Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Top Cited Papers
- 3 April 2014
- journal article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 61 (2), 318-324
- https://doi.org/10.1016/j.jhep.2014.03.030
Abstract
No abstract availableFunding Information
- Instituto de Salud Carlos III (PI11/01830)
- Instituto de Salud Carlos III
- Instituto de Salud Carlos III (FI09/00510)
- University of Barcelona (APIF RD63/2006)
This publication has 28 references indexed in Scilit:
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary StudyPLOS ONE, 2012
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in ItalyHepatology, 2011
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- Drug therapy: SorafenibHepatology, 2010
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with SorafenibThe Oncologist, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988